Newsletter | November 7, 2025

11.07.25 -- The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation

SPONSOR

Join Jon O'Connell and experts on this Cell & Gene Live event, exploring whether minimum viability can help gene therapy developers make smarter sourcing decisions — from research-grade production through clinical and commercial phases, where cost and quality can make or break a product. Registration is free with support from Roche CustomBiotech.

FOCUS ON CLINICAL TRIALS

The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation

As the cell therapy space evolves beyond T cells, allogeneic natural killer (NK) cell therapies are emerging as a scalable and accessible approach in cancer immunotherapy. Experts Raphael Ognar and Tracy Ryan discuss how their teams are advancing the field through distinct yet complementary strategies. The dynamic discussion highlighted the scientific innovation, technological differentiation, and patient-centered vision driving the next generation of allogeneic NK cell therapies.

The Power Of AI To Improve Clinical Trial Monitoring

By analyzing patient data sets, AI enhances predictive analytics, supports real-time patient alerts, and strengthens continuous monitoring — improving the effectiveness of clinical trial oversight.

U.S. Oncologists See Promise In CGTs, But Barriers Loom

Explore the findings of a survey of 124 U.S. oncologists focused on better understanding the current use of cell and gene therapies (CGTs) and possible barriers to future adoption.

Can AI Move Beyond Surface-Level Insights: Part Two

In Part Two of this conversation with Yochi Slonim, we explore how AI is evolving from generating ideas that anyone can access to building disease models that leverage proprietary data.

The Evolving Landscape Of Oncology Drug Development

Oncology drug development is accelerating through precision medicine, biotechnological innovation, and novel modalities like ADCs, immunotherapies, and radiopharmaceuticals, improving outcomes amid cancer incidence.

Data-Driven Physician Engagement For Ultra-Rare Diseases

How can an effective partnership help you leverage advanced data analytics to address the challenges of clinical trials focused on ultra-rare diseases? See how we harness advanced data analytics and expert collaboration.

Why Asia Should Be Your Next Trial Destination

Many U.S. oncology sponsors are expanding their late-phase trials into Asia to secure access to rich patient pools, leverage efficient regulatory pathways, and save time and money in the clinic.

A Practical Guide To Patient Recruitment Excellence

Top-performing clinical trials treat recruitment as a science — thinking like patients, acting fast, and engaging communities with intention, not outdated tactics like bulletin board flyers.

How To Partner With Your CRA For Best Trial Outcomes

An effective partnership with your CRA hinges on open, early communication, transparency, and collaboration to proactively solve challenges, ensuring patient safety and successful, compliant trial outcomes.

Redefining Accessibility For Pediatric Patients

Clinical trials for pediatric patients benefit from flexible delivery at safe locations, reducing participation burdens, enhancing family engagement, and improving retention and outcomes.

Digging Through The Hype: Can AI/ML Assist Clinical Development?

AI has great potential to enhance the efforts of your team members by accelerating data interactions. Watch this webinar and discover how AI can improve clinical trial outcomes and data management.

CLINICAL TRIALS SOLUTIONS

IVD And CDx: Comprehensive Services From Research To Regulatory - Precision for Medicine

Starting A New Study? This One's For You - ClinAI

Your Trial Is In Jeopardy. Time Is Critical. - 20/20 Onsite

Central IRB Services - BRANY

Your Global CRO Partner In Oncology And Hematology - TFS HealthScience

FOCUS ON SUPPLY CHAIN

New Guide Aims To Build Robust Framework For Digital Validation Tools

The ISPE's new guide addresses software for managing digital assets related to qualification, verification, validation, and compliance assurance, establishing robust frameworks.

A Comparative Analysis Between Liquid Nitrogen And Mechanical Freezers

Uncover the differences between liquid nitrogen and mechanical cryogenic freezers, and learn how each method supports scientific, medical, and industrial storage needs.

Understanding The Cold Durability Performance Of Fluoropolymer Bags

Although polymer bags are an excellent choice for cold chain use, not all polymer films perform the same way, even if their specifications rate them for use at low temperatures.

SUPPLY CHAIN SOLUTIONS

Blast Freezing And Thawing For Any Primary Packaging - Single Use Support

EVENTS

Advancing the Future of Cell & Gene Therapy

This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines.

 

Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now

Connect With Cell & Gene: